1   **Biomarkers of insulin resistance and their performance as predictors of treatment response**

2   **in adults with risk factors for type 2 diabetes.**

4   RJ Brogan[1,2], O Rooyackers[3], BE Phillips[4], B Twelkmeyer[3], LM Ross[5], PJ Atherton[3], WE

5   Kraus[5], JA Timmons[2,6*] and IJ Gallagher[7*]

Affiliations

[1]Anaesthesia, Pain and Perioperative Medicine, Fiona Stanley Hospital, Perth, WA, Australia

[2]Augur Precision Medicine LTD, Stirling, Scotland

[3]Division of Anesthesiology and Intensive Care, CLINTEC, Karolinska Institutet, Sweden

[4]Clinical, Metabolic and Molecular Physiology Research Group, School of Medicine, University

of Nottingham, Derby, England

[5]Duke University School of Medicine, Durham, NC, USA

[6]Faculty of Medicine and Dentistry, Queen Mary University of London, London, England

[7]Center for Biomedicine and Global Health, Edinburgh Napier University, Edinburgh, Scotland

* Senior Authors

Key words: T2DM, Insulin resistance, biomarkers, regression, Bayesian projective prediction

Corresponding author: robert.brogan@health.wa.gov.au

Abstract

Insulin Resistance (IR) is a component of the pathogenesis of type 2 diabetes mellitus (T2DM),

and risk factor for cardiovascular and neurodegenerative diseases. Amino acid and lipid

metabolomic IR diagnostics associate with future T2DM risk in epidemiological cohorts. Whether

these assays can accurately detect altered IR following treatment has not been established. In the

present study we evaluated the ability of metabolomic diagnostics to predict altered IR following

exercise treatment. We evaluated the performance of two distinct insulin assays and built

combined clinical and metabolomic IR diagnostics. These were utilised to stratify IR status in the

pre-intervention fasting samples in three independent cohorts (META-PREDICT (MP, n=179),

STRRIDE-AT/RT (S-2, n=116) and STRRIDE-PD (S-PD, n=149)). Linear and Bayesian

projective prediction strategies were used to evaluate biomarkers for fasting insulin and HOMA2-

IR and change in fasting insulin with treatment. Both insulin assays accurately quantified

international standard insulin (R^2>0.99), yet agreement for fasting insulin was less congruent

(R^2=0.65). Only the high-sensitivity ELISA assay could identify the mean effect of treatment on

fasting insulin. Clinical-metabolomic models were statistically related to fasting insulin (R^2 0.33

– 0.39) but had modest capacity to classify HOMA2-IR at a clinically relevant threshold.

Furthermore, no model predicted treatment responses in any cohort. Thus, we demonstrate that the

choice of insulin assay is critical when quantifying the influence of life-style on fasting insulin,

while none of the clinical-metabolomic biomarkers, validated in cross-sectional data, are suitable

for monitoring longitudinally changes in IR status.

Introduction

Chronic hyperinsulinaemia, a feature of type 2 diabetes mellitus (T2DM), contributes to a cycle of events driving further insulin resistance (IR) [1], promoting cardiovascular [2] and neurodegenerative diseases [3]. Extreme IR also represents a distinct category of T2DM [4]. Lifestyle based treatments are effective at reducing the risk of developing T2DM. [5–8] Such programs, typically involving exercise training, modify IR with high intra-individual variability. [9–14] Similar variability is observed in response to drug treatment. [15,16] While monitoring the efficacy of treatment on glucose tolerance in large cohorts is relatively straightforward [17], the same cannot be said for monitoring insulin action. [18,19] Furthermore, the varying characteristics of commonly used insulin assays complicate comparison across studies. [20,21] There are clear clinical definitions for diagnosing T2DM and impaired glucose tolerance (IGT) but less so for IR, possibly due to the lack of widespread measurement of insulin. This is problematic because IR is distinct from glucose intolerance and can precede T2DM and slowly developing age-related diseases by decades and thus there is an urgent need to enable tracking over time IR. [22,23]

This need for cost-effective practical IR diagnostics has stimulated the development of several clinical [24] and molecular prototypes, including assays relying on branched-chain amino acids (BCAA)[25–28], plasma lipoproteins[29–31] and multi-protein signatures.[32] The abundance of several circulating amino acid and plasma lipids have been incorporated into statistical models that predict IR in cross-sectional, prospective or retrospective analyses (i.e. predict T2DM risk).[25–27,29–31,33] Circulating BCAA are particularly attractive as surrogates for IR because disrupted catabolism of individual BCAA have been mechanistically and causally linked to IR, cardiovascular and

neurodegenerative disease processes in recent years [13,28,34–43]. It remains unclear how well

abundance of BCAA in the circulation reflects the mechanistic role of BCAA within the key tissues

responsible for their catabolism and therefore in turn their ability to track with changes in

metabolic fitness.

In addition to predicting IR, it would therefore be ideal if metabolic 'risk' biomarkers could

reliably associate with improvements in IR following treatment, so that non-responders could be

reallocated to alternative treatments. [14–16,44,45] There have been attempts to establish if plasma

BCAA abundance tracks treatment responses yielding conflicting conclusions, partly because

existing studies have been too small to reliably explore such relationships. [46,47] Determinants of

insulin action also reflect a combination of distinct acute mechanisms in the hours post-exercise,

and more stable long-term adaptive changes [48] – such as increased tissue vascularisation. [49] Such

temporal influences have not been considered when evaluating these novel biomarkers.

Immediately post-exercise insulin action and glucose tolerance can be impaired, while insulin

responses to an oral glucose tolerance test (OGTT) appear lowest 72hr following the previous

exercise training session.[50]

In the present analyses we have assessments of IR within 24hr and 48-72hr after the last training

session of chronic exercise training that was effective in reducing group mean HOMA2IR. The

idea is that novel biomarkers should offer practical (e.g. cost, simplicity) advantages over

laboratory insulin assays, and if they can be shown to predict longitudinal changes in IR, then

efforts to configure low-cost standardised assay from minimally invasive sampling would be

motivated. In the present multi-study analysis, we evaluated, in hundreds of individuals at-risk for

T2DM, the performance of established BCAA and lipid biomarkers, combined with simple to

measure clinical phenotypes to estimate fasting IR and predict changes in insulin following

supervised lifestyle interventions.[9,12,51,52] We established that choice of insulin assay is critical for

capturing interactions between exercise status and fasting insulin, while plasma biomarkers of IR

status, from cross-sectional and prospective studies, are unable to track with treatment responses.

Results

Demographic, blood and metabolomic data for the three independent cohorts - STRRIDE AT/RT

(S-2), STRRIDE-PD (S-PD) and MP - are presented in **Table 1.**

Comparison of insulin assay and metabolomics assay performance

A long-standing challenge is that commercial assays for insulin show distinct specificity and

sensitivity profiles, with no agreement to move to a single standard assay.[20,21] Some historical

insulin assays, utilised in exercise intervention studies (e.g. HERITAGE)[53] or included in genome-

wide association modelling,[54] do not show molecular associations consistent with modern more

specific insulin assays.[13] We produced a large-scale comparison of two typical insulin assays (the

immunoassay based automated analyzer (Immulite 2000) and a manual high sensitivity ELISA kit

(Dako, Stockholm, Sweden), run in parallel on samples obtained before and after exercise-training

that reduced IR.[55] Both Immulite 2000 and Dako ELISA showed near perfect ($>R^2=0.99$)

correlation with the international WHO standard for insulin (National Institute for Biological

Standards and Control, **Figure S1A-B**). No cross reaction with c-peptide standard was detected

(data not shown). When plotting insulin values from the same fasting samples, there was moderate

agreement between the two assays (R^2=0.65, **Figure S2**). Critically, insulin measured using the

high-sensitivity ELISA was able to detect a group mean reduction following exercise training,

while the Immulite 2000 immune-assay could not (**Figure 1**). All the subsequent analyses relied

on the data generated by the Dako high-sensitivity ELISA (produced in a single laboratory).

Biomarker association with fasting insulin and HOMA2-IR status

Predictor variables were selected based on the literature summarised above, and availability in all

three cohorts. Linear regression was performed to explore individual relationships between fasting

insulin and the selected clinical and metabolomic biomarkers (**Figure 2**; full results in **Table S1**).

In MP, all pre-selected variables other than age (p=0.09) reached statistical significance for

association with fasting insulin (age is a reliable covariate but the age-range in MP was limited).

In S-2 $\log_{10}$ BMI (p<0.001), fasting glucose (p<0.001), HDL (p=0.007), TAG (p<0.001) and amino

acids (isoleucine (ILE) p=0.0005, leucine (LEU) p=0.006, valine (VAL) p<0.001, alanine (ALA)

p=0.0027) were linearly associated with fasting insulin. Similar levels of associations were

observed in the S-PD cohort, except for ALA (p=0.068). For multi-variable predictors of fasting

insulin (or HOMA2-IR) and predictors of treatment responses, variables which showed a

statistically significant association in one or more of the cohorts were considered (as each was

supported with published evidence for having an association in cross-sectional cohorts).

As each study used some distinct metabolomic methods (see Methods) we performed multivariable

linear regression and logistic regression with K-fold cross validation (k=10) separately in MP, S-

2 and S-PD cohorts. Four models were considered; a baseline model (age, BMI and gender), a

BCAA model (age, BMI, gender and sum of BCAA), a lipid model (age, BMI, gender, HDL, LDL

and TAG) and finally, a combined model (age, BMI, gender, BCAA, HDL, LDL and TAG). The

combined model estimated fasting insulin (R^2 0.33 – 0.39), with the results in agreement with

previous observations (**Table 2**). Fasting glucose was excluded when predicting IR status. For IR

ROC analysis, insulin sensitive (IS, HOMA2-IR <1.3) and insulin resistant (IR, HOMA2-IR ≥1.3)

was defined based on results from a large population study (n=95,540) where HOMA2-IR ≥1.3

was associated with an increased risk for the development of T2DM over a median of 4.7y (hazard

ratio of 3.2 (95% CI 1.9-5.3)). [56] The four models were assessed in each cohort for their ability to

classify IS vs IR (**Figure 3**). The baseline model had no discriminatory performance in S-2, so the

metabolomics variables improved that model substantially, however metabolomics did not add

further to the clinical model ROC performance in MP or S-PD, and the best models had a modest

Cohens Kappa (**Table S2**). This illustrates that even though BCAA and lipid models statistically

associate with IR status, they do not contribute to a clinically useful model.

Biomarker based prediction of IR status in response to lifestyle intervention.

We established that each biomarker statistically associated with fasting insulin in each study

(**Table S1**) and as reported by others. Finally, we examined the utility of these biomarkers for

predicting exercise treatment related insulin responses in IR. For this analysis we were able to

include changes in fasting glucose (easy and inexpensive to measure) as we did not rely on the

HOMA model. **Figure 4** displays the univariable linear relationships of changes in clinical and

metabolomic biomarkers with changes in fasting insulin as measured with the high sensitivity

ELISA over an exercise intervention in all three cohorts (**Figure S3** provides the correlation

coefficients (including for individual amino acids). To examine the classification utility of

individual and combinations of biomarkers we built Bayesian linear models, independently for

each cohort, modelling change in fasting insulin after each intervention. The models included age and changes over the intervention in individual BCAA, fasting glucose, BMI, lipids, systolic blood pressure and alanine. The full models ("reference" models) were considered as the optimum solution to the prediction task.[57] The posterior predictive distributions showed the models performed well and were able to predict data like that of the observed data (**Fig 4A-C**). Using projective prediction, we found that the biomarkers did not, however, improve predictive performance over a null model i.e. the intercept term (**Figure 4D-F**).[58] Thus, change in biomarkers (alone or additively combined) could not predict change in fasting insulin following an exercise intervention.

Discussion

Development of a cost-effective diagnostic for insulin sensitivity would help better understand the aetiology of T2DM and aligning clinical practice with the key recommendations of the International Diabetes Federation, namely early detection and prevention of pre-diabetes.[59] Hyperinsulinaemia drives altered insulin receptor expression potentially leading to further IR.[1] IR in turn contributes to cardiovascular disease[2] and dementia risk.[3] Insulin is not, however, routinely measured in the clinic and thus crucial information regarding the temporal nature of IR is lacking. Previous work has identified several potential biomarkers for IR in cross-sectional and prospective settings. [25–27,29–31,33] The present study extends this body of work to evaluate these IR biomarkers in the context of their ability to accurately classify changes in fasting insulin in response to exercise (MP and S2) or lifestyle (S-PD) based treatment for individuals with multiple risk-factors for T2DM.

Importance of the insulin assay

To our knowledge we are the first to demonstrate the importance of insulin assay choice on

detecting changes in fasting insulin in large scale treatment studies. The MP cohort represents a

typical group of sedentary middle-aged individuals with multiple risk factors for T2DM.[12] We note

that the Immulite 2000 immunoassay was unable to detect exercise induced improvements in

fasting insulin, while concurrent measurements using a high sensitivity ELISA assay did. Notably

neither assay demonstrated any cross-reactivity with c-peptide and they both performed well in a

standard curve analysis. The American Diabetes Association attempted to reach a consensus on

standardizing the measurement of insulin.[20,21] Our analysis indicates that if environmental

influences or treatment effects on fasting insulin levels are to be captured, a high-sensitivity ELISA

assay should be utilised. We have previously reported that some older insulin assays, with

undocumented specificity (e.g. HERITAGE),[60] were unsuitable for genomic association

analysis.[13] Indeed, it is plausible that the use of insulin assays insensitive to variations across the

'normal' range of fasting insulin, or with cross-reactivity for C-peptide, have undermined genome-

wide association modelling of fasting insulin.[61] While suboptimal insulin assays will not be

voluntarily retired by manufacturers, it would seem sensible that the research community adopt

the use of high-sensitivity assays for studies of fasting insulin in all situations (other than extreme

hyperinsulinaemia)[20,21] especially when subtle gene-environment interactions are of interest to

study.

Metabolomic components of the IR biomarker models

There is a well-established positive correlation between individual circulating BCAA and greater

IR [25–27] and pathways that control BCAA catabolism have gained interest as possible targets for

reversing IR.[28,62,63] Furthermore, BCAA have been combined with clinical parameters to

reportedly increase the performance of models that predict both IR and risk of T2DM.[29,31,33] We

previously identified, using four independent cohorts, a transcriptional signature including BCAA

catabolism pathway genes, that related to IR after adjustment for age, VO2max and BMI (n=564).

We also found that in response to four independent lifestyle interventions (n=196), expression of

16 genes in human skeletal muscle changed in proportion to improvements in insulin sensitivity,

with 25% of those related to BCAA metabolism.[13] While this makes sense, as by mass, skeletal

muscle has the largest capacity for BCAA catabolism in humans [64] it does not provide evidence

that circulating levels of BCAA's will dynamically reflect tissue responses to insulin. In fact,

insulin mediated BCAA clearance may also rely on other organs including the liver.[65]

In a recent study, Lee *et al* claimed that baseline plasma BCAA levels related to change in glucose

infusion rate during a hyperinsulinaemic−euglycaemic clamp (a measure of insulin sensitivity and

liver fat content [47]). This was despite no change in total plasma BCAA levels and an increase in

muscle BCAA catabolism pathway gene expression. We also found no change in group mean

blood BCAA abundance with any exercise training protocol (**Table 1**), which might be

understandable as only ~40% of subjects demonstrate a numerical improvement in HOMA2-IR

and some demonstrate an increase in IR.[12,13] Nevertheless we did not find that changes in combined

plasma BCAA were able to predict changes in IR status. This observation is consistent with earlier

modelling approaches applied to the STRRIDE cohorts, where the combination of BCAA and

lipid-based IR biomarkers could not predict changes in a measure of insulin sensitivity.[17] Various

other combinations of BCAA and protein metabolites have been considered as IR models and

while some shared variance has been observed,[66] these are most likely attributable to random

differences in small cohorts. Using energy restriction to modify IR, we recently reported that group

mean differences in plasma BCAA abundance were also unchanged, despite group mean

improvements in IR. [66] All of these observations contrast with a previous study, relying on a sample

size a 10th of the present work, where changes in plasma BCAA abundance did track with improved

IR status.[46]

We attempted several modelling strategies, including several distinct clinical and metabolomic

variables, and modelled both fasting insulin and HOMA2-IR values to ensure our negative

conclusions were rigorous. We used Bayesian modelling and projective prediction [67,68] to establish

a sparse model that retained the ability to provide useful predictions of circulating insulin changes.

Projective prediction uses the predictions from the reference (full) model to identify a subset of

variables with predictive ability as close as possible to that of the full model. We were unable to

identify any set of variables useful for predicting change in circulating insulin after lifestyle

intervention using this strategy. Conventional regression modelling, against changes in HOMA2-

IR also failed to identify a useful model. We can conclude that the present clinical-metabolic

measures are not useful for classifying a HOMA2-IR threshold value indicative of 3-fold elevated

risk of T2DM over 5 years, nor track altered fasting insulin with life-style interventions. This is

even though our ELISA-based insulin values were strongly associated with causal molecular

drivers of T2DM and insulin signalling in tissue samples.[13]

Clinical evaluation of IR biomarker models

Diagnosing IR is challenging not least because defining IR remains controversial. The gold

standard method is commonly described as the 'clamp' technique or intravenous glucose tolerance

test.[19,69] However, substantial resources are required for this such that it is rarely used for diagnosis

and by their nature both can be supraphysiological (re levels of insulin). Alternative IR indices

exist and include the homeostatic model assessment (HOMA and HOMA2 [70,71], Matsuda index [72]

and the disposition index (DI).[73] These are not used in clinical practice, largely due to a lack of

routine measurement of insulin. Although several epidemiological studies use HOMA and

HOMA2 for modelling IR, there is limited basis for defining a clinical cut off value. Several studies

unwisely use a percentile cut off identified within their individual cohort, and then apply ROC

curve analysis to determine the threshold for a diagnosis of IR and then relate this to relative risk

for relevant clinical outcomes e.g. progression to T2DM or cardiovascular disease. As a result, the

HOMA IR threshold used across studies, to define 'at risk', has varied from 1.8 to 3.9 depending

on the population studied and methods used.[18] This represents a form of model overfitting.

It was estimated that a HOMA2-IR more than 1.3 represented a hazard ratio of >3.2 for developing

T2DM over ~5 years in 95,450 subjects.[74] This analysis is the largest study to date linking a

particular HOMA2-IR value to incipient diabetes and we used this cutoff in the present study.

Interestingly, in exploratory analysis, 83% of those with the most severe IR (HOMA2-IR$\geq$2.4)

were not classified as metabolically compromised when using fasting glucose or their 2-hour-

glucose OGTT data.[12] The current reliance on glucose-centric risk assessment also limits our

ability to identify and hence intervene in those people with the "least effective" response to insulin

(defined as the totality of all of insulin's key physiology). Nevertheless, all the surrogate variables

investigated in the present study have limited ability to *diagnose* IR in a cross-sectional setting,

and *no* ability to track changes in IR with life-style treatment.

In summary, we evaluated multiple predictive models for IR, including models incorporating well

validated cholesterol species and BCAA. These models failed to forecast change in IR status

following supervised lifestyle modification. A limitation of our study is the limited metabolomic

variables gathered across cohorts (although this would mainly impact on the identification of novel

metabolites to consider). Nevertheless, any new blood based metabolic disease biomarkers

reported to track improvements in insulin sensitivity across multiple independent cohorts would

require substantial independent clinical studies to validate beyond the level of the models evaluated

in the present study.

Materials and Methods

Clinical Cohorts

The MP cohort consisted of 189 active participants, recruited as previously described from five

geographical regions across Europe.[12] All clinical methods relied on cross-site standard operating

procedures (SOPs), while insulin and metabolomic measures were performed in a single central

laboratory. All participants were classified as sedentary (<600 metabolic equivalents (METs)

min·wk^{-1}) using a modified International Physical Activity Questionnaire,[75] and had a fasting

blood glucose level consistent with World Health Organisation (WHO) criteria for impaired

glucose tolerance (5.5 < IGT <7.0 mmol·l^{-1}), and/or a BMI >27 kg·m^{-2}. Participants were excluded

if they had evidence of active cardiovascular, cerebrovascular, respiratory, gastrointestinal or renal

disease or had a history of malignancy, coagulation dysfunction, musculoskeletal or neurological

disorders, recent steroid or hormone replacement therapy, or any condition requiring long-term

drug prescriptions. Exercise training was supervised and consisted of three high intensity cycling

sessions per week for 6 weeks as previously described.[12] Prior to the baseline assessments,

participants were instructed to refrain from exercise for three days. Supine blood pressure (Omron

M2, Omron Healthcare, Kyoto, Japan) and resting heart rate (RHR) were determined as the

average of three consecutive measurements. Blood glucose (from a dorsal hand vein) was analysed

before and during an (OGTT) using a YSI 2300 STAT Plus glucose analyser (Yellow Springs Inc.

Ohio, USA). Blood was collected in lithium heparin spray-coated vacutainers (Becton Dickinson,

New Jersey, USA) for analysis of insulin. The MP trial registration code is NCT01920659. The

STRRIDE cohorts were composed of sedentary middle-aged individuals at risk of developing

cardio-metabolic disease. [9,51,52] Following baseline assessments, each subject was randomized to

one of a variety of exercise training programs for six to eight months with or without a modified

diet.[9,51,52] Pre and post clinical and physiological assessments and outcomes were as previously

reported.[9,51,52]

Plasma sample insulin analysis

The samples from MP and the STRIDDE studies were analysed using high sensitivity insulin

ELISA (Dako A/S, Sweden). Two levels of QC solutions were run for insulin. Coefficients of

variation (CV) were acceptable; 4.68-8.03 % on both levels. As we were also using the

automated analyser (Immulite 2000) for analyses of all OGTT time points for insulin and c-

peptide from the MP study, we also assessed available fasting sample profiles using this lower

sensitivity immune-assay. To assure comparability of the results, we independently checked the

assay performance for cross detection of insulin and C-peptide. The WHO standard for insulin

and C-peptide were obtained from NIBSC (The National Institute for Biological Standards and

Control). A dilution series for both analytes was prepared and run on Dako ELISA and Immulite

2000. The diluted WHO insulin standards were subjected to the same procedure as the samples.

The results for both Immulite 2000 and Dako ELISA showed an acceptable correlation of

expected versus measured concentration with $R^2 = 0.9995$ and $R^2 = 0.9923$ for Immulite 2000

and Dako ELISA, respectively. The results are presented in **Figure S1**. No cross reaction

between insulin and c-peptide were detected. The two assays were in broad agreement over the

large concentration range of insulin used in this standard assay evaluation protocol **Figure S2**.

Plasma sample metabolomic analysis

Metabolomic analyses for MP has not been previously published (other than fasting glucose and

insulin). All samples were randomized for sample preparation and analyses resulting in an equal

distribution of all centres and possible responders and non-responders. We used hierarchical

clustering of metabolomic variables to highlight that there was no systematic centre specific bias

(**Figure S4**). All samples were taken after an overnight fast as arterialized venous blood and run

in duplicate. Results within ±20% CV were accepted unless otherwise stated; if this limit was not

met the sample was rerun. Quality controls (QC) were run for all analyses and with each batch of

sample preparation to ensure stable performance of the analysis procedure. QC for all analyses

included in house controls made from pooled EDTA plasma from healthy controls originating

from a previous study. The following methods were used for each metabolite. Sample analysis

used a Konelab 20XTi photospectrometer (Thermo Fisher Scientific, Thermo Electron Oy, Vantaa

Finland) for high density lipoprotein HDL cholesterol, LDL cholesterol and triacylglycerides

(TAG). Amino acids were analyzed using HPLC 2695 (Waters, Watford, UK) with online

derivatization and a fluorescence detector 474 (Waters, Watford, UK) using a method described

previously.[76,77] Fatty acids were analyzed using ultra-high performance liquid chromatography (Ultimate 3000 UHPLC, Thermo Fisher Scientific, Germering, Germany) coupled to a TSQ Vantage with electrospray ionization (ESI) and triple quadrupole mass spectrometer (MS/MS) (Thermo Fisher Scientific, San Jose, CS, USA). For the blood obtained from the STRRIDE cohorts' samples were analysed for plasma glucose concentration at the research site (Duke University, USA) using a Beckman–Coulter DxC600 clinical analyser (Brea, CA, United States). Insulin was analyzed (in the Stockholm lab) using the high sensitivity insulin ELISA assay (Dako Denmark A/S, Glostrup, Denmark); and fasted plasma samples were analysed on 400 MHz nuclear magnetic resonance profilers at LipoScience, now LabCorp (Morrisville, NC, United States), as previously described [78]. The lipoprotein parameters and the BCAA were identified by retrospectively analysing digitally stored spectra using the newly developed NMR-based lipoprotein LP4 algorithm, which correlate with mass spectrometry methods.[79]

As distinct methodologies were utilised for the metabolomic analyses between MP and STRRIDE cohorts we explore the compatibility of the common metabolomic data used in our diagnostic models. For S-2 and S-PD, two methodologies were utilised for lipid related metabolomics and Bland-Altman analysis was performed to assess measurement agreement between HDL and TAG with NMR versus mass spectroscopy (**Figure S5-8**). There was good linear agreement between methods for HDL (S-2 r^2 0.96, p<0.001; S-PD r^2 0.89, p<0.001) and TAG (S-2 r^2 0.99, p<0.001; S-PD r^2 0.95, p<0.001). Bland-Altman analysis revealed a mean measurement error of -0.06 mmol/L for HDL (S-2 **Figure 5B**, S-PD **Figure S7B**) and +0.04mmol/L (S-2 **Figure 6B**, S-PD **Figure S8B**) for TAG with 95% of observations within 1.96 standard deviation of mean. Work by Wolak-Dinsmore *et al* demonstrated that NMR overestimates VAL and LEU by >25% (mean

value) and underestimates ILE by 10-15% (mean value) and while MS was used in MP, S-2 and

S-PD relied on NMR for BCAA quantification. Based on these known systematic differences,[79]

modelling was performed independently in each cohort using cross-validation methods.

Statistical Modelling

Raw data from the clinical chemistry analyses was analysed with GraphPad Prism 5 (Software

MacKiev, 2007, version 5.01) and more advanced analysis was accomplished using STATISTICA

10 (StatSoft Inc., 2011, version 10.0.228.2). All subsequent analysis was performed in R version

4.1.1 and 4.3.2. We utilised conventional and Bayesian strategies to model data in the present

work. Potentially predictive variables were selected based on known associations with IR and

T2DM. Linear regression modelling was applied to investigate associations between dependent

and independent variables. Briefly, after reducing each dataset to complete cases common

variables were identified across all three cohorts. The criterion for considering a clinically useful

variable was pragmatic – it had to be something that could be measured cheaply and reliably in a

primary care setting. Laboratory measures like maximal aerobic capacity related to IR status in

some but not all cohorts but was not considered because of the time and cost required to measure

it accurately. Several variables were selected based on these ease/low-cost criteria; some variables

were dropped because of high collinearity (e.g. systolic blood pressure was retained in favour of

diastolic blood pressure and mean arterial pressure in the Bayesian analysis). We removed

participants with obesity class III (BMI >40kg/m^2) for the Bayesian analysis and all continuous

variables were normalised. The latter steps were carried out using the tidymodels R package

(10.32614/CRAN.package.tidymodels) and applied consistently across all datasets. Collinearity

between variables was checked for each dataset separately **(Figure S3)**. Apart from BCAA in the

MP dataset there were no pairwise correlations with an absolute value >0.5. Linear models were

built with student-t priors on both the intercept and slope coefficient terms (df=3, mean=0 and

scale=4). These were mildly informative on the scale of the normalised data. Details are in the

supplementary material.

We built Bayesian multivariable linear models using the brms package to predict change in

circulating insulin using relevant clinical variables, circulating BCAA levels and selective lipids.[80]

These full models were considered reference models. We then used projective prediction to

identify a subset of variables with predictive performance as close as possible to that of the

reference model.[58] Briefly projective prediction first generates a solution path - the variable

ranking - for each sub model examined. Next a leave-one-out cross-validation process determines

the predictive performance of each sub model along the predictor ranking.

Funding

The clinical data utilised in this study was funded by multiple sources: European Union Seventh

Framework Programme (META-PREDICT, HEALTH-F2-2012-277936); STRRIDE II

(NCT00275145) by NHLBI grant HL-057354 and STRRIDE-PD (NCT00962962) by NIDDK

DK-081559 and R01DK081559. The data modelling was supported by Augur Precision Medicine

LTD.

Competing interests

None declared. JT is a major shareholder in APM, however there is no commercial link between

APM and the present study. There are no other financial conflicts of interest to disclose.

Contributions

RJB, JAT, OR and IJG conceptualized aims and designed the analysis strategy. All authors

contributed to the project design, data collection and/or pre-processing. RJB and IJG performed

data analysis and JAT contributed to interpretation. JAT and RJB wrote the first draft and JAT,

RJB and IJG produced a full manuscript that all authors contributed to and have read and approved

the final manuscript. JT wrote the HEALTH-F2-2012-277936 grant application.

Data and code availability

Some or all datasets generated during and/or analysed during the current study are not publicly

available but are available from the corresponding author on reasonable request. Data and the

analysis script can be found at **10.5281/zenodo.13819578.**

References

1.   Cen HH, Hussein B, Botezelli JD, et al. Human and mouse muscle transcriptomic analyses
identify insulin receptor mRNA downregulation in hyperinsulinemia-associated insulin resistance.
FASEB Journal. 2022;36(1). doi:10.1096/fj.202100497RR

2.   Wamil M, Coleman RL, Adler AI, McMurray JJV, Holman RR. Increased Risk of Incident Heart
Failure and Death Is Associated With Insulin Resistance in People With Newly Diagnosed Type 2
Diabetes: UKPDS 89. *Diabetes Care*. 2021;44(8):1877-1884. doi:10.2337/DC21-0429

3.   Folch J, Olloquequi J, Ettcheto M, et al. The Involvement of Peripheral and Brain Insulin
Resistance in Late Onset Alzheimer's Dementia. *Front Aging Neurosci*. 2019;11(September):1-16.
doi:10.3389/fnagi.2019.00236

4.   Dennis JM, Shields BM, Henley WE, Jones AG, Hattersley AT. Disease progression and
treatment response in data-driven subgroups of type 2 diabetes compared with models based on
simple clinical features: an analysis using clinical trial data. *Lancet Diabetes Endocrinol*.
2019;7(6):442-451. doi:10.1016/S2213-8587(19)30087-7

5.   Knowler WC, Fowler SE, Hamman RF, et al. 10-year follow-up of diabetes incidence and weight
loss in the Diabetes Prevention Program Outcomes Study. *Lancet*. 2009;374(9702):1677-1686.

6.   Wing RR, Bolin P, Brancati FL, et al. Cardiovascular effects of intensive lifestyle intervention in
type 2 diabetes. *New England Journal of Medicine*. 2013;369(2):145-154.
doi:10.1056/NEJMoa1212914

7.   Uusitupa M, Peltonen M, Lindström J, et al. Ten-year mortality and cardiovascular morbidity in
the Finnish Diabetes Prevention Study - Secondary analysis of the randomized trial. *PLoS One*.
2009;4(5):1-8. doi:10.1371/journal.pone.0005656

8.   Hivert MF, Christophi CA, Franks PW, et al. Lifestyle and metformin ameliorate insulin
sensitivity independently of the genetic burden of established insulin resistance variants in
diabetes prevention program participants. *Diabetes*. 2016;65(2):520-526. doi:10.2337/db15-0950

9.   Ross LM, Slentz CA, Kraus WE. Evaluating Individual Level Responses to Exercise for Health
Outcomes in Overweight or Obese Adults. *Front Physiol*. 2019;10. doi:10.3389/fphys.2019.01401

10.   Huffman KM, Slentz CA, Bateman LA, et al. Exercise-induced changes in metabolic
intermediates, hormones, and inflammatory markers associated with improvements in insulin
sensitivity. *Diabetes Care*. 2011;34(1):174-176. doi:10.2337/dc10-0709

11.   AbouAssi H, Slentz C a, Mikus CR, et al. The Effects of Aerobic, Resistance and Combination
Training on Insulin Sensitivity and secretion in Overweight Adults from STRRIDE AT/RT: A
Randomized Trial. *J Appl Physiol (1985)*. 2015;118(919):jap.00509.2014.
doi:10.1152/japplphysiol.00509.2014

12.   Phillips BE, Kelly BM, Lilja M, et al. A practical and time-efficient high-intensity interval training
program modifies cardio-metabolic risk factors in adults with risk factors for type II diabetes.
Front Endocrinol (Lausanne). 2017;8(SEP):1-11. doi:10.3389/fendo.2017.00229

13.   Timmons JA, Atherton PJ, Larsson O, et al. A coding and non-coding transcriptomic perspective
on the genomics of human metabolic disease. *Nucleic Acids Res*. 2018;46(15):7772-7792.
doi:10.1093/nar/gky570

14.   Álvarez C, Ramírez-Campillo R, Ramírez-Vélez R, Izquierdo M. Effects and prevalence of
nonresponders after 12 weeks of high-intensity interval or resistance training in women with
insulin resistance: a randomized trial. *J Appl Physiol*. 2017;122:985-996.
doi:10.1152/japplphysiol.01037.2016.-Our

15.   Sears DD, Hsiao G, Hsiao A, et al. Mechanisms of human insulin resistance and
thiazolidinedione-mediated insulin sensitization. *Proc Natl Acad Sci U S A*. 2009;106(44):18745-
18750. doi:10.1073/pnas.0903032106

16.   Ustinova M, Ansone L, Silamikelis I, et al. Whole-blood transcriptome profiling reveals signatures
of metformin and its therapeutic response. *PLoS One*. 2020;15(8 August):1-17.
doi:10.1371/journal.pone.0237400

17.   Ross LM, Slentz CA, Zidek AM, et al. Effects of Amount, Intensity, and Mode of Exercise
Training on Insulin Resistance and Type 2 Diabetes Risk in the STRRIDE Randomized Trials.
Front Physiol. 2021;12(February):1-10. doi:10.3389/fphys.2021.626142

18.   Tang Q, Li X, Song P, Xu L. Optimal cut-off values for the homeostasis model assessment of
insulin resistance (HOMA-IR) and pre-diabetes screening: Developments in research and
prospects for the future. *Drug Discov Ther*. 2015;9(6):380-385. doi:10.5582/DDT.2015.01207

19.   Ferrannini E, Mari A. How to measure insulin sensitivity. *J Hypertens*. 1998;16(7):895-906.
doi:10.1097/00004872-199816070-00001

20. Manley SE, Stratton IM, Clark PM, Luzio SD. Comparison of II human insulin assays:
Implications for clinical investigation and research. *Clin Chem*. 2007;53(5):922-932.
doi:10.1373/clinchem.2006.077784

21. Miller WG, Thienpont LM, Van Uytfanghe K, et al. Toward standardization of insulin
immunoassays. *Clin Chem*. 2009;55(5):1011-1018. doi:10.1373/clinchem.2008.118380

22. Thambisetty M, Metter EJ, Yang A, et al. Glucose intolerance, insulin resistance, and pathological
features of Alzheimer disease in the Baltimore Longitudinal Study of Aging. *JAMA Neurol*.
2013;70(9):1167-1172. doi:10.1001/jamaneurol.2013.284

23. Rodríguez-Mañas L, Angulo J, Carnicero JA, El Assar M, García-García FJ, Sinclair AJ. Dual
effects of insulin resistance on mortality and function in non-diabetic older adults: findings from
the Toledo Study of Healthy Aging. *Geroscience*. 2022;44(2):1095-1108. doi:10.1007/s11357-
021-00384-4

24. Clausen JO, Borch-Johnsen K, Ibsen H, et al. Insulin sensitivity index, acute insulin response, and
glucose effectiveness in a population-based sample of 380 young healthy Caucasians: Analysis of
the impact of gender, body fat, physical fitness, and life-style factors. *Journal of Clinical
Investigation*. 1996;98(5):1195-1209. doi:10.1172/JCI118903

25. Zheng Y, Ceglarek U, Huang T, et al. Weight-loss diets and 2-y changes in circulating amino
acids in 2 randomized intervention trials. *American Journal of Clinical Nutrition*.
2016;103(2):505-511. doi:10.3945/ajcn.115.117689

26. Shah SH, Bain JR, Muehlbauer MJ, et al. Association of a peripheral blood metabolic profile with
coronary artery disease and risk of subsequent cardiovascular events. *Circ Cardiovasc Genet*.
2010;3(2):207-214. doi:10.1161/CIRCGENETICS.109.852814

27. Bloomgarden Z. Diabetes and branched-chain amino acids: What is the link? *J Diabetes*.
2018;10(5):350-352. doi:10.1111/1753-0407.12645

28. Newgard CB, An J, Bain JR, et al. A branched-chain amino acid-related metabolic signature that
differentiates obese and lean humans and contributes to insulin resistance. *Cell Metab*.
2009;9(4):311-326. doi:10.1016/J.CMET.2009.02.002

29. Floegel A, Stefan N, Yu Z, et al. Identification of serum metabolites associated with risk of type 2
diabetes using a targeted metabolomic approach. *Diabetes*. 2013;62(2):639-648.

30. Shalaurova I, Connelly MA, Garvey WT, Otvos JD. Lipoprotein insulin resistance index: a
lipoprotein particle-derived measure of insulin resistance. *Metab Syndr Relat Disord*.
2014;12(8):422-429. doi:10.1089/MET.2014.0050

31. Flores-Guerrero JL, Gruppen EG, Connelly MA, et al. A newly developed diabetes risk index,
based on lipoprotein subfractions and branched chain amino acids, is associated with incident type
2 diabetes mellitus in the prevend cohort. *J Clin Med*. 2020;9(9):1-17. doi:10.3390/jcm9092781

32. Zanetti D, Stell L, Gustafsson S, et al. Plasma proteomic signatures of a direct measure of insulin
sensitivity in two population cohorts. *Diabetologia*. 2023;66(9):1643-1654. doi:10.1007/s00125-
023-05946-z

33. Wang TJ, Larson MG, Vasan RS, et al. Metabolite profiles and the risk of developing diabetes.
Nat Med. 2011;17(4):448-453. doi:10.1038/NM.2307

34. White PJ, Lapworth AL, McGarrah RW, et al. Muscle-Liver Trafficking of BCAA-Derived
Nitrogen Underlies Obesity-Related Glycine Depletion. *Cell Rep*. 2020;33(6).
doi:10.1016/j.celrep.2020.108375

35. Zhou M, Shao J, Wu CY, et al. Targeting BCAA catabolism to treat obesity-associated insulin
resistance. *Diabetes*. 2019;68(9):1730-1746. doi:10.2337/db18-0927

36. Lin C, Sun Z, Mei Z, et al. The causal associations of circulating amino acids with blood pressure:
a Mendelian randomization study. *BMC Med*. 2022;20(1). doi:10.1186/s12916-022-02612-w

37. Biswas D, Duffley L, Pulinilkunnil T. Role of branched-chain amino acid–catabolizing enzymes in
intertissue signaling, metabolic remodeling, and energy homeostasis. *FASEB Journal*.
2019;33(8):8711-8731. doi:10.1096/fj.201802842RR

38. White PJ, McGarrah RW, Herman MA, Bain JR, Shah SH, Newgard CB. Insulin action, type 2
diabetes, and branched-chain amino acids: A two-way street. *Mol Metab*. 2021;52.
doi:10.1016/J.MOLMET.2021.101261

39. Jang C, Oh SF, Wada S, et al. A branched-chain amino acid metabolite drives vascular fatty acid
transport and causes insulin resistance. *Nat Med*. 2016;22(4):421-426. doi:10.1038/nm.4057

40. Lynch CJ, Adams SH. Branched-chain amino acids in metabolic signalling and insulin resistance.
Nat Rev Endocrinol. 2014;10(12):723-736. doi:10.1038/nrendo.2014.171

41. Timmons JA, Anighoro A, Brogan RJ, et al. A human-based multi-gene signature enables
quantitative drug repurposing for metabolic disease. *Elife*. 2022;11. doi:10.7554/eLife.68832

42. Soto M, Cai W, Konishi M, Kahn CR. Insulin signaling in the hippocampus and amygdala
regulates metabolism and neurobehavior. *Proc Natl Acad Sci U S A*. 2019;116(13):6379-6384.
doi:10.1073/pnas.1817391116

43. Chen W, Huang Q, Lazdon EK, et al. Loss of insulin signaling in astrocytes exacerbates
Alzheimer-like phenotypes in a 5xFAD mouse model. *Proceedings of the National Academy of
Sciences*. 2023;120(21):e2220684120. doi:10.1073/PNAS.2220684120

44. Mutch DM, Temanni MR, Henegar C, et al. Adipose gene expression prior to weight loss can
differentiate and weakly predict dietary responders. *PLoS One*. 2007;2(12).
doi:10.1371/journal.pone.0001344

45. Newton RL, Johnson WD, Larrivee S, et al. A Randomized Community-based Exercise Training
Trial in African American Men: Aerobic Plus Resistance Training and Insulin Sensitivity in
African American Men. *Med Sci Sports Exerc*. 2020;52(2):408-416.
doi:10.1249/MSS.0000000000002149

46. Glynn EL, Piner LW, Huffman KM, et al. Impact of combined resistance and aerobic exercise
training on branched-chain amino acid turnover, glycine metabolism and insulin sensitivity in
overweight humans. *Diabetologia*. 2015;58(10):2324-2335. doi:10.1007/s00125-015-3705-6

47. Lee S, Gulseth HL, Langleite TM, et al. Branched-chain amino acid metabolism, insulin
sensitivity and liver fat response to exercise training in sedentary dysglycaemic and
normoglycaemic men. *Diabetologia*. 2021;64(2):410-423. doi:10.1007/s00125-020-05296-0

48. Dimenna FJ, Arad AD. The acute vs. chronic effect of exercise on insulin sensitivity: nothing lasts
forever. *Cardiovasc Endocrinol Metab*. 2021;10(3):149-161.
doi:10.1097/XCE.0000000000000239

49. Zheng C, Liu Z. Vascular function, insulin action, and exercise: an intricate interplay. *Trends*
Endocrinol Metab. 2015;26(6):297-304. doi:10.1016/J.TEM.2015.02.002

50. King DS, Baldus PJ, Sharp RL, Kesl LD, Feltmeyer TL, Riddle MS. Time course for exercise-
induced alterations in insulin action and glucose tolerance in middle-aged people. *J Appl Physiol*
(1985). 1995;78(1):17-22. doi:10.1152/JAPPL.1995.78.1.17

51. Slentz CA, Bateman LA, Willis LH, et al. Effects of exercise training alone vs a combined
exercise and nutritional lifestyle intervention on glucose homeostasis in prediabetic individuals: a
randomised controlled trial. *Diabetologia*. 2016;59(10):2088-2098. doi:10.1007/s00125-016-4051-
z

52. Slentz CA, Bateman LA, Willis LH, et al. Effects of aerobic vs. resistance training on visceral and
liver fat stores, liver enzymes, and insulin resistance by HOMA in overweight adults from
STRRIDE AT/RT. *Am J Physiol Endocrinol Metab*. 2011;301(5):1033-1039.
doi:10.1152/ajpendo.00291.2011

53. An P, Teran-Garcia M, Rice T, et al. Genome-wide linkage scans for prediabetes phenotypes in
response to 20 weeks of endurance exercise training in non-diabetic whites and blacks: The
HERITAGE Family Study. *Diabetologia*. 2005;48(6):1142-1149. doi:10.1007/s00125-005-1769-4

54. Bouchard C, Rankinen T, Timmons JA. Genomics and genetics in the biology of adaptation to
exercise. *Compr Physiol*. 2011;1(3):1603-1648. doi:10.1002/cphy.c100059

55. Phillips BE, Kelly BM, Lilja M, et al. A practical and time-efficient high-intensity interval training
program modifies cardio-metabolic risk factors in adults with risk factors for type II diabetes.
Front Endocrinol (Lausanne). 2017;8(SEP). doi:10.3389/fendo.2017.00229

56. Marott SCW, Nordestgaard BG, Tybjaerg-Hansen A, Benn M. Causal associations in type 2
diabetes development. *Journal of Clinical Endocrinology and Metabolism*. 2019;104(4):1313-
1324. doi:10.1210/jc.2018-01648

57. Pavone F, Piironen J, Bürkner PC, Vehtari A. Using reference models in variable selection.
Comput Stat. 2023;38(1):349-371. doi:10.1007/s00180-022-01231-6

58. Piironen J, Paasiniemi M, Vehtari A. Projective inference in high-dimensional problems:
Prediction and feature selection. *Electron J Stat*. 2020;14(1):2155-2197. doi:10.1214/20-EJS1711

59. *IDF Strategic Plan*.; 2023.

60. Keller P, Vollaard NBJ, Gustafsson T, et al. A transcriptional map of the impact of endurance
exercise training on skeletal muscle phenotype. *J Appl Physiol*. 2011;110(1):46-59.
doi:10.1152/japplphysiol.00634.2010

61. Manning AK, Hivert MF, Scott RA, et al. A genome-wide approach accounting for body mass
index identifies genetic variants influencing fasting glycemic traits and insulin resistance. *Nat*
Genet. 2012;44(6):659-669. doi:10.1038/ng.2274

62. Crossland H, Smith K, Idris I, Phillips BE, Atherton PJ, Wilkinson DJ. Exploring mechanistic
links between extracellular branched-chain amino acids and muscle insulin resistance: an in vitro
approach. *Am J Physiol Cell Physiol*. 2020;319(6):C1151-C1157.
doi:10.1152/AJPCELL.00377.2020

63. Roth Flach RJ, Bollinger E, Reyes AR, et al. Small molecule branched-chain ketoacid
dehydrogenase kinase (BDK) inhibitors with opposing effects on BDK protein levels. *Nat*
Commun. 2023;14(1). doi:10.1038/S41467-023-40536-Y

64.   Sitryawan A, Hawes JW, Harris RA, Shimomura Y, Jenkins AE, Hutson SM. A molecular model
612   of human branched-chain amino acid metabolism. *Am J Clin Nutr*. 1998;68(1):72-81.
613   doi:10.1093/AJCN/68.1.72

614   65.   Shin AC, Fasshauer M, Filatova N, et al. Brain Insulin Lowers Circulating BCAA Levels by
615   Inducing Hepatic BCAA Catabolism. *Cell Metab*. 2014;20(5):898-909.
616   doi:10.1016/J.CMET.2014.09.003

617   66.   Sayda MH, Abdul Aziz MH, Gharahdaghi N, et al. Caloric restriction improves glycaemic control
618   without reducing plasma branched-chain amino acids or keto-acids in obese men. *Sci Rep*.
619   2022;12(1). doi:10.1038/S41598-022-21814-Z

620   67.   Pavone F, Piironen J, Bürkner PC, Vehtari A. Using reference models in variable selection.
621   *Comput Stat*. 2023;38(1):349-371. doi:10.1007/S00180-022-01231-6/FIGURES/9

622   68.   Piironen J, Paasiniemi M, Vehtari A. Projective inference in high-dimensional problems:
623   Prediction and feature selection. *https://doi.org/101214/20-EJS1711*. 2020;14(1):2155-2197.
624   doi:10.1214/20-EJS1711

625   69.   Tripathy D, Cobb JE, Gall W, et al. A novel insulin resistance index to monitor changes in insulin
626   sensitivity and glucose tolerance: The ACT NOW study. *Journal of Clinical Endocrinology and*
627   *Metabolism*. 2015;100(5):1855-1862. doi:10.1210/jc.2014-3824

628   70.   Wallace TM, Levy JC, Matthews DR, Homa T. Use and Abuse of HOMA Modeling. *Diabetes*
629   *Care*. 2004;27(6):1487-1495.

630   71.   Levy JC, Matthews DR, Hermans MP. Correct homeostasis model assessment (HOMA)
631   evaluation uses the computer program. *Diabetes Care*. 1998;21(12):2191-2192.
632   doi:10.2337/DIACARE.21.12.2191

633   72.   Matsuda M, Defronzo RA. Insulin Sensitivity Indices Obtained From Comparison with the
634   euglycemic insulin clamp. *Diabetes Care*. 1999;22(9):1462-1470.

635   73.   Utzschneider KM, Prigeon RL, Faulenbach M V., et al. Oral Disposition index predicts the
636   development of future diabetes above and beyond fasting and 2-h glucose levels. *Diabetes Care*.
637   2009;32(2):335-341. doi:10.2337/dc08-1478

638   74.   Marott SCW, Nordestgaard BG, Tybjaerg-Hansen A, Benn M. Causal associations in type 2
639   diabetes development. *Journal of Clinical Endocrinology and Metabolism*. 2019;104(4):1313-
640   1324. doi:10.1210/jc.2018-01648

641   75.   Hagströmer M, Oja P, Sjöström M. The International Physical Activity Questionnaire (IPAQ): a
642   study of concurrent and construct validity. *Public Health Nutr*. 2006;9(6):755-762.

643   76.   Godel H, Graser T, Földi P, Pfaender P, Fürst P. Measurement of free amino acids in human
644   biological fluids by high-performance liquid chromatography. *J Chromatogr A*. 1984;297:49-61.
645   doi:https://doi.org/10.1016/S0021-9673(01)89028-2

646   77.   Vesali RF, Klaude M, Rooyackers O, Wernerman J. Amino acid metabolism in leg muscle after an
647   endotoxin injection in healthy volunteers. *Am J Physiol Endocrinol Metab*. 2005;288:360-364.
648   doi:10.1152/ajpendo.00248.2004.-Decreased

649   78.   Jeyarajah EJ, Cromwell WC, Otvos JD. Lipoprotein particle analysis by nuclear magnetic
650   resonance spectroscopy. *Clin Lab Med*. 2006;26(4):847-870. doi:10.1016/J.CLL.2006.07.006

651   79.   Wolak-Dinsmore J, Gruppen EG, Shalaurova I, et al. A novel NMR-based assay to measure
652   circulating concentrations of branched-chain amino acids: Elevation in subjects with type 2
653   diabetes mellitus and association with carotid intima media thickness. *Clin Biochem*. 2018;54:92-
654   99. doi:10.1016/J.CLINBIOCHEM.2018.02.001

655   80.   Bürkner PC. brms: An R package for Bayesian multilevel models using Stan. *J Stat Softw*.
656   2017;80. doi:10.18637/jss.v080.i01

657
658

Table 1.

	MP		S2		S-PD	
	Pre	**Post**	**Pre**	**Post**	**Pre**	**Post**
N	**179**	**109**	**116**	**85**	**149**	**122**
Gender (f:m)	100:79	58:51	58:58	43:41	89:60	71:51
Age	38 (18)	38 (18)	50 (14.5)	50 (17)	59 (11)	59 (12)
Weight (kg)	91.5 (20.1)	91.6 (21)	88 (17.5)	85.5 (13.2)	86.2 (17.4)	83.7 (16.5)
BMI	31 (5.5)	30.6 (4.766)	30.4 (4.88)	30 (5)	30.2 (4.45)	29.4 (4.6)
SBP (mmHg)	125 (14)	121 (16)	119 (16)	121 (18)	126 (16)	122 (21)
DPB (mmHg)	78 (13)	77 (14)	80 (14)	80 (14)	75 (12)	72 (13)
MAP (mmHg)	94 (13)	90 (12)	93 (15)	80 (14)	91 (13)	89 (13)
Resting HR	70 (12)	68 (12)	74 (16)	NA	NA	NA
VO2 max (mL/min/kg)	27.5 (10)	30.2 (11)	26.7 (7.56)	30.7 (9.6)	23.8 (7.05)	26 (8.25)
Fasting glucose (mmol/L)	4.61 (0.43)	4.6 (0.4)	5.26 (0.65)	5.33 (0.77)	5.78 (0.78)	5.81 (0.74)
2-hour glucose (mmol/L)	6.67 (1.51)	6.32 (1.9)	NA	NA	7.66 (3.43)	7.22 (2.3)
Fasting insulin (imm)	84.4 (65.4)	78.7 (51.7)	55.7 (43.7)	44.3 (33.5)	236 (234)	195 (199)
Fasting insulin (ELISA)	57.7 (42.5)	50.9 (37.6)	30.7 (43.7)	36.6 (33.2)	49.6 (58.4)	40.3 (47.2)
HOMA2 IR	1.2 (0.9)	1.07 (0.8)	1.07 (1)	0.81 (0.71)	1.12 (1.3)	0.95 (1.07)
Sum BCAA (μmol/L)	424 (133)	438 (139)	424 (90.4)	465 (85.5)	439 (99.1)	429 (96.1)
Leucine (μmol/l)	120 (40.6)	126 (39)	153 (36.2)	171.7 (39.5)	148 (37.9)	148 (35.1)
Isoleucine (μmol/L)	62.89 (22.6)	63.8 (21.7)	66.8 (20.1)	65.6 (22.5)	62.8 (19.7)	59.8 (14.5)
Valine (μmol/l)	239 (70.2)	247 (75.5)	208 (51.8)	230 (50)	221 (50.2)	220 (49.5)
HDL (mmol/L)	1.02 (0.39)	1.04 (0.4)	0.9 (0.33)	1.12 (0.33)	1.06 (0.39)	1.11 (0.37)
LDL (mmol/L)	2.64 (0.99)	2.5 (0.96)	2.45 (0.87)	2.72 (0.75)	3.12 (0.96)	2.96 (0.82)
TAG (mmol/L)	1.17 (0.75)	1.09 (0.72)	1.4 (0.85)	1.25 (0.78)	1.3 (0.83)	1.18 (0.95)
ALA (μmol/L)	321 (107)	326 (127)	419 (110)	405 (150)	399 (98)	390 (123)

Table 1. **Demographics. Median and IQR.** All available samples were utilised for baseline modelling. In each analysis, only subjects with complete data were used in the pre/post modelling, resulting in ~ 20% fewer subjects than recruited or completing the intervention.

666   **Table 2**.

Cohort	Model	RMSE	MAE	r^2	Adj r^2	p value
MP n=179	1	0.208	0.167	0.272	0.255	<0.001
	2	0.205	0.164	0.302	0.282	<0.001
	3	0.208	0.161	0.309	0.281	<0.001
	4	0.206	0.161	0.327	0.295	<0.001
S-2 n=116	1	0.267	0.215	0.265	0.238	<0.001
	2	0.271	0.221	0.298	0.266	<0.001
	3	0.255	0.208	0.366	0.325	<0.001
	4	0.254	0.208	0.389	0.343	<0.001
S-PD n=149	1	0.295	0.237	0.202	0.18	<0.001
	2	0.281	0.227	0.265	0.239	<0.001
	3	0.293	0.229	0.304	0.269	<0.001
	4	0.291	0.223	0.339	0.301	<0.001
Model 1 = age+gender+$\log_{10}$BMI+fasting glucose Model 2 = model 1 + sumBCAA Model 3 = model 1 + HDL+LDL+TAG Model 4 = model 1 + HDL+LDL+TAG+sumBCAA						

667
668
669   **Table 2.** K-fold cross validation multiple linear regression predicting baseline $\log_{10}$ fasting insulin from
670   clinical and metabolomic variables.
671

Figure 1. Insulin assay statistical performance for identifying differences in pre vs post exercise training samples (MP cohort). Fasting insulin (pmol/L) was measured using a high sensitivity ELISA (left) and the Immulite 2000 automated analyser (right). P-values are calculated from paired t-tests on log10 fasting insulin (pmol/L). Only the ELISA could detect a significant treatment effect.

678
679

680
681
682 **Figure 2.** Scatter plots with OLS line of best fit (95% CI shaded) between log10 fasting insulin
683 and clinical and metabolic variables. A) MP, B) S-2 and C) S-PD
684

Figure 3. Utility of baseline clinical and metabolomic variables to classify HOMA2-IR status at
1.3 unit threshold reflecting the analysis of Marott et al. K-fold cross validation logistic
regression ROC curves for A. MP, B. S-2 and C. S-PD.

689
690
691 **Figure 4.** Scatter plots with OLS line of best fit (95% CI shaded) between delta fasting insulin
692 and clinical and metabolic variables. A) MP, B) S-2 and C) S-PD
693

Figure 5. Left panel; Posterior predictive distributions for A. MP, B. S-2 and C. S-PD. Right panel; Expected log predictive density (Elpd, upper trace) and root mean square error (RMSE, lower trace) for D. MP, E. S-2 and F. S-PD. Elpd and RMSE are shown with 95% nominal coverage intervals.

699 **Table S1**. Linear regression modelling using log10 fasting insulin as dependant variable. Note the sample sizes reflecting all subjects
700 with data for each individual clinical parameter or metabolomic measure. In final integrated modelling only subjects with all
701 completes values were included.

META-PREDICT							
Model	**n**	**Intercept p**	**Intercept estimate**	**Estimates**	**95% CI**	**p**	**Adj r^2**
Age	188	<0.0001	1.8737	-0.0032	-0.0069 – 0.0005	0.0918	0.010
Gender	186	<0.0001	1.8254	-0.1227	-0.1928 – -0.0527	**0.0007**	0.056
BMI (log10)	188	0.5690	-0.2714	1.3532	0.7283 – 1.9781	**<0.0001**	0.084
SBP	175	<0.0001	1.1684	0.0048	0.0016 – 0.0080	**0.0038**	0.042
DBP	174	<0.0001	1.2888	0.0060	0.0020 – 0.0099	**0.0030**	0.044
MAP	174	<0.0001	1.1370	0.0066	0.0026 – 0.0106	**0.0013**	0.053
Fasting glucose	188	0.1037	-51.5267	25.7240	12.2694 – 39.1787	**0.0002**	0.066
HDL	185	<0.0001	2.0214	-0.2481	-0.3604 – -0.1358	**<0.0001**	0.089
LDL	184	<0.0001	1.5896	0.0599	0.0157 – 0.1041	**0.0082**	0.032
Triglycerides	187	<0.0001	1.6140	0.1110	0.0615 – 0.1604	**<0.0001**	0.091
Sum of BCAA	184	<0.0001	1.3981	0.0008	0.0005 – 0.0011	**<0.0001**	0.123
Isoleucine	184	<0.0001	1.4579	0.0045	0.0027 – 0.0063	**<0.0001**	0.115
Leucine	184	<0.0001	1.4408	0.0025	0.0015 – 0.0036	**<0.0001**	0.106
Valine	184	<0.0001	1.3818	0.0015	0.0009 – 0.0021	**<0.0001**	0.126

Model	n	Intercept p	Intercept estimate	Estimates	95% CI	p	Adj r²
Alanine	184	<0.0001	1.5930	0.0005	0.0001 – 0.0009	**0.0148**	0.027

STRRIDE-2							
Model	**n**	**Intercept p**	**Intercept estimate**	**Estimates**	**95% CI**	**p**	**Adj r²**
Age	128	<0.0001	1.7792	-0.0027	-0.0082 – 0.0027	0.3227	0
Gender	128	<0.0001	1.7628	-0.0886	-0.2063 – 0.0290	0.1386	0.009
BMI (log10)	128	0.0024	-2.8007	3.0012	1.7913 – 4.2110	**<0.0001**	0.154
SBP	111	<0.0001	1.2972	0.0029	-0.0017 – 0.0076	0.2139	0.005
DBP	111	0.0001	1.1314	0.0066	-0.0004 – 0.0136	0.0650	0.022
MAP	111	0.0002	1.1428	0.0055	-0.0009 – 0.0119	0.0911	0.017
Fasting glucose	118	0.0001	0.9260	0.1394	0.0582 – 0.2206	**0.0009**	0.083
HDL	128	**<0.0001**	1.8172	-0.2448	-0.4208 – -0.0687	**0.0068**	0.049
LDL	128	**<0.0001**	1.8172	-0.0606	-0.1486 – 0.0274	0.1753	0.007
Triglycerides	128	**<0.0001**	1.4320	0.1329	0.0677 – 0.1981	**0.0001**	0.107
Sum of BCAA	126	**<0.0001**	0.8578	0.0017	0.0009 – 0.0024	**0.0001**	0.117
Isoleucine	126	**<0.0001**	1.2102	0.0066	0.0029 – 0.0102	**0.0005**	0.085
Leucine	126	**<0.0001**	1.1699	0.0027	0.0008 – 0.0047	**0.0064**	0.051
Valine	126	**<0.0001**	0.8261	0.0035	0.0019 – 0.0050	**<0.0001**	0.13
Alanine	128	**<0.0001**	1.2359	0.0010	0.0003 – 0.0016	**0.0027**	0.062

				STRRIDE PD			
Model	n	Intercept p	Intercept estimate	Estimates	95% CI	p	Adj r^2
Age	155	<0.0001	1.9753	-0.0046	-0.0116 – 0.0024	0.1944	0.005
Gender	155	<0.0001	1.7253	-0.0395	-0.1455 – 0.0665	0.463	0
BMI (log10)	155	0.1983	-1.2123	1.9683	0.7168 – 3.2198	**0.0023**	0.053
SBP	134	<0.0001	1.2980	0.0032	-0.0009 – 0.0074	0.1260	0.010
DPB	134	<0.0001	1.4408	0.0035	-0.0025 – 0.0096	0.2507	0.002
MAP	134	<0.0001	1.2897	0.0045	-0.0014 – 0.0105	0.1365	0.009
Fasting glucose	154	0.2343	0.3187	0.2357	0.1464 – 0.3251	**<0.0001**	0.146
HDL	153	<0.0001	2.0821	-0.3326	-0.4602 – -0.2051	**<0.0001**	0.144
LDL	151	<0.0001	1.5234	0.0568	-0.0180 – 0.1316	0.1355	0.008
Triglycerides	153	<0.0001	1.5573	0.0961	0.0311 – 0.1610	**0.0040**	0.047
Sum of BCAA	155	<0.0001	1.1048	0.0014	0.0007 – 0.0021	**0.0001**	0.091
Isoleucine	155	<0.0001	1.2519	0.0071	0.0038 – 0.0104	**<0.0001**	0.098
Leucine	155	<0.0001	1.3715	0.0022	0.0004 – 0.0041	**0.0159**	0.031
Valine	155	<0.0001	0.9665	0.0033	0.0021 – 0.0046	**<0.0001**	0.147
Alanine	155	<0.0001	1.4536	0.0006	-0.0000 – 0.0013	0.0675	0.015

705 **Table S2** - K-fold cross validation logistic regression model statistics for combined model predicting insulin resistance (HOMA2 IR
706 ≥ 1.3) using age, BMI, gender, sum of branched chain amino acids, HDL, LDL and triglycerides.
707

	MP	S2	S-PD
Accuracy (95% CI)	0.676 (0.602-0.744)	0.707 (0.615-0.788)	0.644 (0.562-0.721)
Kappa	0.339	0.347	0.27
Sensitivity	0.58	0.512	0.563
Specificity	0.755	0.822	0.706
PPV	0.662	0.629	0.59
NPV	0.685	0.741	0.682
Prevalence	0.453	0.371	0.43
Detection rate	0.263	0.19	0.242

709
710 **Figure S1.** Performance of the insulin assays. A) (Immulite using titration international insulin
711 standard), B) (ELISA using titration international insulin standard), and C) Immulite vs ELISA
712 standard curve values using international insulin standard once converted to uIU/ml)

713
714 **Figure S2.** Correlation of participant fasting insulin measured using Dako ELISA and Immulite
715 2000 assays.
716
717

718
Figure S3. Correlation plots showing strength of correlation between the variables used in the
generation of linear models to predict change in circulating insulin across lifestyle interventions.
A. MP, B. S-2 and C. S-PD.

723
724   **Figure S4.** Hierarchical clustering of subjects by their metabolomic profile demonstrating that
725   there is no centre specific bias.
726
727

728
Figure S5-6. **S5)** S-2 HDL assay performance. A) Comparison of mass spectroscopy and nuclear
magnetic resonance (NMR) measurement of HDL using linear regression. B) Bland-Altman plot
to estimate of bias with 95% confidence interval shown in blue, with upper (green) and lower
(red) limits. **S6)**. S-2 TAG assay performance. A) Comparison of mass spectroscopy and nuclear
magnetic resonance (NMR) measurement of TAG using linear regression. B) Bland-Altman plot
to estimate of bias with 95% confidence interval shown in blue, with upper (green) and lower
(red) limits.
736

737
Figure S7-8. **S7)** S-PD HDL assay performance. A) Comparison of mass spectroscopy and
nuclear magnetic resonance (NMR) measurement of HDL using linear regression. B) Bland-
Altman plot to estimate of bias with 95% confidence interval shown in blue, with upper (green)
and lower (red) limits. **S8)**. S-PD TAG assay performance. A) Comparison of mass spectroscopy
and nuclear magnetic resonance (NMR) measurement of TAG using linear regression. B) Bland-
Altman plot to estimate of bias with 95% confidence interval shown in blue, with upper (green)
and lower (red) limits.
745